VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
){kind=link}